Stepped Collaborative Care for PTSD
(TSOS 8 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test a new approach called Stepped Collaborative Care to reduce symptoms of posttraumatic stress disorder (PTSD) and decrease emergency room visits. Participants will join one of two groups: one receiving usual care and the other receiving Stepped Collaborative Care, which includes medication, therapy, and personalized support. The trial seeks individuals who have been injured, exhibit significant PTSD symptoms, and speak English or Spanish.
As an unphased trial, this study offers a unique opportunity to contribute to innovative PTSD treatment research.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that stepped collaborative care is generally well-received by patients. In a study with 635 participants, this treatment significantly improved PTSD symptoms, indicating its safety and effectiveness for many people. Although the study focused on symptom reduction, it found no serious safety issues. Individual experiences may vary, but current evidence supports the safety of this approach for managing PTSD symptoms.12345
Why are researchers excited about this trial?
Researchers are excited about the Stepped Collaborative Care approach for PTSD because it offers a tailored, multi-faceted treatment plan that adapts to each patient's needs. Unlike the standard care, which often involves isolated interventions like medication or psychotherapy, this method combines posttraumatic concern elicitation, proactive care management, medication, and psychotherapy elements. This comprehensive strategy aims to tackle not only PTSD symptoms but also related mental health issues, potentially leading to more effective and faster recovery for patients.
What evidence suggests that this trial's treatments could be effective for PTSD?
Research has shown that Stepped Collaborative Care, which participants in this trial may receive, can help reduce symptoms of posttraumatic stress disorder (PTSD) in some patients. Specifically, studies found that this approach significantly reduced PTSD symptoms six months after treatment, particularly for non-white or Hispanic patients. This method combines care management, medication, and therapy to address PTSD and related issues. Although the benefits were clear at six months, the reduction in symptoms was not as strong after a year. Overall, this approach aims to make treatment more accessible and effective for those dealing with PTSD.12346
Who Is on the Research Team?
Douglas Zatzick, MD
Principal Investigator
University of Washington
Are You a Good Fit for This Trial?
This trial is for adults over 18 who've been hospitalized for a traumatic injury, have high PTSD symptoms, and meet certain risk criteria. They must speak English or Spanish and live in specific Western US states. Excluded are those under 18, non-trauma patients, non-English/Spanish speakers, cognitively impaired individuals, prisoners, residents outside the specified states with insufficient contact info or safety concerns due to violence history.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a stepped collaborative care intervention including care management, medication, and psychotherapy targeting PTSD and comorbidity
Follow-up
Participants are monitored for safety and effectiveness after treatment with follow-up interviews at 1-, 3-, 6-, and 12-months post-injury
What Are the Treatments Tested in This Trial?
Interventions
- American College of Surgeons (ACS) Required Screening and Referral (Usual Care)
- Stepped Collaborative Care
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator